ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Vigil Neuroscience Inc

Vigil Neuroscience Inc (VIGL)

3.60
-0.10
(-2.70%)
At close: 13 November 8:00AM
3.60
0.00
( 0.00% )
After Hours: 10:00AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.60
Bid
3.53
Offer
3.94
Volume
133,892
3.54 Day's Range 3.65
2.47 52 Week Range 6.98
Market Cap
Previous Close
3.70
Open
3.65
Last Trade
10
@
3.63
Last Trade Time
08:47:29
Financial Volume
US$ 478,613
VWAP
3.5746
Average Volume (3m)
90,323
Shares Outstanding
40,879,485
Dividend Yield
-
PE Ratio
-1.77
Earnings Per Share (EPS)
-2.02
Revenue
-
Net Profit
-82.64M

About Vigil Neuroscience Inc

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple ther... Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Dover, Delaware, USA
Founded
-
Vigil Neuroscience Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIGL. The last closing price for Vigil Neuroscience was US$3.70. Over the last year, Vigil Neuroscience shares have traded in a share price range of US$ 2.47 to US$ 6.98.

Vigil Neuroscience currently has 40,879,485 shares in issue. The market capitalisation of Vigil Neuroscience is US$151.25 million. Vigil Neuroscience has a price to earnings ratio (PE ratio) of -1.77.

VIGL Latest News

Vigil Neuroscience to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer’s Disease on...

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.25-6.493506493513.854.063.522407753.69953452CS
40.061.694915254243.544.123.3797924403.81610234CS
120.12.857142857143.54.123.1903233.58499672CS
260.3611.11111111113.246.062.473140104.16867687CS
52-1.83-33.70165745865.436.982.472166833.94141731CS
156-8.4-701218.272.181127005.73482876CS
260-8.4-701218.272.181127005.73482876CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MVSTMicrovast Holdings Inc
US$ 0.3103
(71.72%)
8.17M
DAVEDave Inc
US$ 79.17
(26.07%)
44.97k
NMHINatures Miracle Holding Inc
US$ 0.1068
(24.62%)
6.45M
RKLBRocket Lab USA Inc
US$ 18.25
(24.49%)
7.33M
CYCCCyclacel Pharmaceuticals Inc
US$ 0.5002
(22.00%)
2.65M
SYRSSyros Pharmaceuticals Inc
US$ 0.3882
(-85.78%)
9.05M
VINOGaucho Group Holdings Inc
US$ 2.35
(-47.19%)
173.18k
VRMVroom Inc
US$ 5.42
(-38.90%)
47.13k
SIBNSI BONE Inc
US$ 11.50
(-26.42%)
4.8k
INSGInseego Corporation
US$ 13.69
(-24.61%)
36.51k
JGLOJP Morgan Global Select Equity ETF
US$ 63.13
(0.00%)
18.88M
SOUNSoundHound AI Inc
US$ 6.99
(-7.54%)
12.3M
LGMKLogicMark Inc
US$ 0.1688
(-5.43%)
9.43M
SYRSSyros Pharmaceuticals Inc
US$ 0.3882
(-85.78%)
9.05M
MVSTMicrovast Holdings Inc
US$ 0.3103
(71.72%)
8.17M

VIGL Discussion

View Posts
Monksdream Monksdream 2 months ago
VIGL under $4
👍️0
Monksdream Monksdream 4 months ago
VIGL under $5
👍️0
Monksdream Monksdream 4 months ago
VIGL under $5
👍️0
MiamiGent MiamiGent 4 months ago
Good insight.
👍️0
Zorro Zorro 5 months ago
More than likely there is an announcement baked into this deal that will allow for the sale of those 7.44 shares at a profit.
👍️ 1
PonkenPlonken PonkenPlonken 5 months ago
Those 3.80 dippers look pretty smart now ;)
👍️ 1
MiamiGent MiamiGent 5 months ago
$VIGL At 12 noon:

Volume
13,927,465
90 Day Avg. Vol.
147,064

9.5 X's 90 DAV
👍️0
MiamiGent MiamiGent 5 months ago
VIGL Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
GLOBENEWSWIRE
2:00 AM ET Jun-27-2024
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock-

- Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies -

- Company expects proceeds to extend cash runway into 2026 -

WATERTOWN, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (VIGL.NaE) , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, is pleased to announce that Sanofi has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company’s Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.

“We are excited by this strategic investment from Sanofi, one of the world’s leading biopharmaceutical companies, for our research and development programs,” said Ivana Magovcevic-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “We view Sanofi’s investment in Vigil as a validation of our promising precision medicine approach led by our two differentiated TREM2 modalities, iluzanebart and VG-3927, and Sanofi has provided valuable capital to help fund our pipeline. We look forward to the opportunity to work with Sanofi as we continue to advance our small molecule TREM2 agonist program.”

“Recent discoveries have highlighted the role of microglial signaling and neuroinflammation in neurodegenerative diseases. TREM2 is a well credentialed microglia target in this context,” said Erik Wallstroem, Sanofi's Global Head of Neurology Development. “The investment in Vigil strengthens our commitment to immunoscience and neuroimmunology.”

In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company’s small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer’s disease.

Based on current projections, the Company expects that the proceeds from Sanofi’s investment will extend its cash runway into 2026.

About Vigil Neuroscience (VIGL.NaE)

Vigil Neuroscience (VIGL.NaE) is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” of Vigil Neuroscience (VIGL.NaE) (“Vigil” or the “Company”) that are made pursuant to the safe harbor provisions of the federal securities laws.......
👍️0
PonkenPlonken PonkenPlonken 5 months ago
they often do this in bio land on those that open a quarter+ up, reverse to 0 and then let them go the days after
👍️ 1
PonkenPlonken PonkenPlonken 5 months ago
agree looking good down here
👍️0
MiamiGent MiamiGent 5 months ago
VIGL In @ 3.83 for the scalp
👍️0
reena969 reena969 5 months ago
VIGL: My guess is that the $7 price target for VIGL will be set for the 9:30 market opening, allowing the algorithm to gradually move it to that price point. 1498 in free left, I'll check back later.
Happy Trading
👍️0
tw0122 tw0122 5 months ago
VIGL chop zone makes sense just read news $7.44 max pain 4.80- 7.41 chop zone

Vigil Neuroscience, Inc. (VIGL) announces that Sanofi (SNY) has made a $40 million strategic investment in the Company at an as-converted price of $7.44 per share of common stock. Sanofi will purchase 537,634 of the Company's Series A non-voting preferred shares, each share of which shall be convertible into ten shares of common stock. The Company will use the proceeds to fund its research and development activities.In connection with the equity investment, Vigil has granted Sanofi the exclusive right of first negotiation (ROFN) for an exclusive license, grant or transfer of rights to research, develop, manufacture and commercialize the Company's small molecule TREM2 agonist program, including its clinical candidate, VG-3927. VG-3927 is currently being evaluated in a phase 1 clinical study for the potential treatment of Alzheimer's disease.Based on current projections, the Company expects that the proceeds from Sanofi's investment will extend its cash runway into 2026.
👍️0
reena969 reena969 5 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665212

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174665196
👍️0
tw0122 tw0122 5 months ago
VIGL 5.50s
👍️0
Monksdream Monksdream 6 months ago
VIGL under $5
👍️0
Monksdream Monksdream 7 months ago
VIGL under $3
👍️0
Terpi Terpi 12 months ago
This one trades this, looks like it may be finding a bottom.
👍️0

Your Recent History

Delayed Upgrade Clock